RINVOQ 15 mg Extended-Release Tablets

RINVOQ (Upadacitinib) 15 mg is a prescription medication used to treat several autoimmune diseases.
It belongs to a class of drugs called Janus kinase (JAK) inhibitors, which work by blocking the action of specific enzymes in the body that contribute to inflammation and immune responses.

Benefits of Use

RINVOQ 15 mg is prescribed for adults with moderate to severe conditions such as:

• Rheumatoid Arthritis (RA)
• Psoriatic Arthritis (PsA)
• Ankylosing Spondylitis (AS)
• Atopic Dermatitis (Eczema)
• Ulcerative Colitis (UC)
• Crohn's Disease (CD)

By targeting specific pathways, RINVOQ helps reduce pain, swelling, and stiffness, improves physical function, and achieves disease control, leading to an improved quality of life for patients.

How to Use

1. Always take RINVOQ 15 mg exactly as prescribed by your healthcare provider.
2. The usual dose is one 15 mg tablet taken once daily, with or without food.
3. Swallow the tablet whole. Do not chew, crush, or divide the tablet, as this may affect its extended-release properties.
4. Do not stop taking RINVOQ without consulting your doctor, as this may worsen your condition.
5. If you miss a dose, take it as soon as you remember. If it is close to the time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at once.

Warnings and Precautions

• Serious Infections: RINVOQ can increase the risk of serious infections that may lead to hospitalization or death. These include tuberculosis (TB), bacterial, fungal, viral, and other opportunistic infections.
• Malignancies: Lymphoma and other malignancies have occurred in patients treated with RINVOQ.
• Major Adverse Cardiovascular Events (MACE): An increased risk of MACE (such as heart attack or stroke) has been observed in some studies, particularly in patients 50 years of age or older with at least one cardiovascular risk factor.
• Thrombosis: Blood clots (venous thromboembolism, VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) have occurred in patients treated with JAK inhibitors, including RINVOQ.
• Mortality: An increased risk of all-cause mortality, including sudden cardiac death, has been observed in some studies.
• Tell your doctor about all your medical conditions, especially if you have an infection, a history of infections, heart problems, cancer, or if you are pregnant, planning to become pregnant, or breastfeeding.
• Inform your doctor about all other medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
• Regular monitoring and follow-up with your doctor are essential during RINVOQ treatment.

Ingredients

Active Ingredient: Upadacitinib 15 mg
Inactive Ingredients: Microcrystalline cellulose, hypromellose, colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, red iron oxide, black iron oxide (exact excipients may vary by formulation).

Product Details

• Form: Extended-release tablets
• Strength: 15 mg
• Pack Size: 30 tablets
• Manufacturer: AbbVie